FBLG FibroBiologics, Inc.

Nasdaq fibrobiologics.com


$ 0.33 $ 0.00 (0 %)    

Thursday, 13-Nov-2025 06:32:47 EST
QQQ $ 619.72 $ 0.00 (0 %)
DIA $ 482.51 $ 0.00 (0 %)
SPY $ 682.06 $ 0.00 (0 %)
TLT $ 89.92 $ 0.00 (0 %)
GLD $ 389.10 $ 0.00 (0 %)
$ 0.3281
$ 0.35
$ 0.33 x 1,100
$ 0.36 x 600
-- - --
$ 0.32 - $ 3.56
1,009,089
na
16.88M
$ 0.73
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 10-31-2025 09-30-2025 10-Q
2 07-31-2025 06-30-2025 10-Q
3 05-14-2025 03-31-2025 10-Q
4 03-31-2025 12-31-2024 10-K
5 11-12-2024 09-30-2024 10-Q
6 08-07-2024 06-30-2024 10-Q
7 05-14-2024 03-31-2024 10-Q
8 02-29-2024 12-31-2023 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

Core News & Articles

HC Wainwright & Co. analyst Matthew Caufield maintains FibroBiologics (NASDAQ:FBLG) with a Buy and lowers the price targ...

Core News & Articles

https://scr.zacks.com/files/News/2025/Zacks_SCR_Research_11042025_FBLG_Bautz.pdf

Core News & Articles

FibroBiologics, Inc. - Common Stock (NASDAQ:FBLG) reported quarterly losses of $(0.13) per share which missed the analyst conse...

Core News & Articles

HC Wainwright & Co. analyst Matthew Caufield reiterates FibroBiologics (NASDAQ:FBLG) with a Buy and maintains $10 price ...

Core News & Articles

D. Boral Capital analyst Jason Kolbert maintains FibroBiologics (NASDAQ:FBLG) with a Buy and maintains $16 price target.

Core News & Articles

FibroBiologics, Inc. (NASDAQ:FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 270+ patents issued ...

Core News & Articles

https://s27.q4cdn.com/906368049/files/News/2025/Zacks_SCR_Research_08052025_FBLG_Bautz.pdf

Core News & Articles

HC Wainwright & Co. analyst Matthew Caufield maintains FibroBiologics (NASDAQ:FBLG) with a Buy and raises the price targ...

Core News & Articles

D. Boral Capital analyst Jason Kolbert maintains FibroBiologics (NASDAQ:FBLG) with a Buy and maintains $16 price target.

Core News & Articles

FibroBiologics, Inc. - Common Stock (NASDAQ:FBLG) reported quarterly losses of $(0.12) per share which missed the analyst conse...

Core News & Articles

D. Boral Capital analyst Jason Kolbert maintains FibroBiologics (NASDAQ:FBLG) with a Buy and maintains $16 price target.

Core News & Articles

D. Boral Capital analyst Jason Kolbert maintains FibroBiologics (NASDAQ:FBLG) with a Buy and maintains $16 price target.

Core News & Articles

D. Boral Capital analyst Jason Kolbert maintains FibroBiologics (NASDAQ:FBLG) with a Buy and maintains $16 price target.

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION